FY2025 Earnings Forecast for ABVX Issued By Lifesci Capital

ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) - Analysts at Lifesci Capital issued their FY2025 earnings per share estimates for shares of ABIVAX Société Anonyme in a note issued to investors on Tuesday, March 25th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings of ($3.14) per share for the year. The consensus estimate for ABIVAX Société Anonyme's current full-year earnings is ($2.83) per share.

ABVX has been the subject of several other reports. Citizens Jmp raised shares of ABIVAX Société Anonyme to a "strong-buy" rating in a report on Wednesday, December 4th. Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. Finally, JMP Securities restated a "market outperform" rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $38.00.

ABIVAX Société Anonyme Price Performance

Shares of ABVX stock traded down $0.39 during trading hours on Wednesday, reaching $6.43. The stock had a trading volume of 152,328 shares, compared to its average volume of 122,945. The stock's fifty day simple moving average is $6.80 and its 200 day simple moving average is $8.34. ABIVAX Société Anonyme has a 12 month low of $5.50 and a 12 month high of $16.63.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABVX. ADAR1 Capital Management LLC lifted its stake in ABIVAX Société Anonyme by 190.1% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company's stock worth $11,078,000 after purchasing an additional 991,781 shares during the last quarter. Caligan Partners LP bought a new stake in ABIVAX Société Anonyme in the 4th quarter worth approximately $5,506,000. JPMorgan Chase & Co. purchased a new stake in ABIVAX Société Anonyme in the fourth quarter worth approximately $5,336,000. Allostery Investments LP bought a new position in ABIVAX Société Anonyme during the fourth quarter valued at approximately $4,328,000. Finally, Nantahala Capital Management LLC grew its position in ABIVAX Société Anonyme by 45.7% during the fourth quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company's stock valued at $10,512,000 after acquiring an additional 450,413 shares during the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.